This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Portfolio Pulse from Avi Kapoor
Several top Wall Street analysts have downgraded their ratings for notable companies, including Celldex Therapeutics, Bumble Inc., HP Inc., Agios Pharmaceuticals, and Udemy. These downgrades reflect changes in analyst sentiment and could impact stock prices.
September 27, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Leerink Partners downgraded Agios Pharmaceuticals from Outperform to Market Perform, reducing the price target from $60 to $56. Shares fell 2%.
The downgrade and reduced price target reflect a less favorable outlook, contributing to a decline in share price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 85
NEGATIVE IMPACT
Wolfe Research downgraded Celldex Therapeutics from Outperform to Peer Perform, leading to an 8.7% drop in share price.
The downgrade from Outperform to Peer Perform by Wolfe Research suggests a less optimistic outlook, which has already resulted in a significant share price drop.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEUTRAL IMPACT
Keybanc downgraded Bumble from Overweight to Sector Weight, but shares gained 1.9%.
Despite the downgrade, Bumble's share price increased, indicating mixed market reactions or other positive factors influencing the stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
B of A Securities downgraded HP from Buy to Neutral, maintaining a price target of $37. Shares gained 2.2%.
The downgrade to Neutral suggests a more cautious outlook, but the maintained price target and share price increase indicate stable investor sentiment.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 85
NEUTRAL IMPACT
Morgan Stanley downgraded Udemy from Equal-Weight to Underweight, cutting the price target from $10 to $7.5. Shares gained 1.3%.
Despite the downgrade and reduced price target, Udemy's share price increased, suggesting other factors may be positively influencing the stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80